Dr. Viraj Lavingia

Dr. Viraj Lavingia is a highly regarded Medical Oncologist known for his expertise in gastrointestinal malignancies. He brings extensive experience in precision oncology, clinical research, and advanced patient management to his practice. As the head of the Department of Oncology at Shalby Hospitals, Dr. Lavingia is dedicated to integrating
innovative therapies into routine care, ensuring patients receive the most advanced and effective treatments available.

• UICC Fellowship: City of Hope, USA – Specialized in hepatic arterial infusion chemotherapy
• Apollo Hospital, Hyderabad – DNB Medical Oncology – 2017
• Breach Candy Hospital, Mumbai – DNB Internal Medicine – 2013
• Smt. NHL Municipal Medical College, Ahmedabad – MBBS – 2007

• Director GI Medical Oncology and Admin Head for Department of Medical Oncology, HCG Cancer Centre, Ahmedabad, April 2022 to September 2023
• Consultant Medical Oncologist (Gastrointestinal services), HCG Cancer Centre, Ahmedabad, May 2018 to March 2022
• Consultant Medical Oncologist, Apollo CBCC, Ahmedabad, November 2017 to May 2018
• DNB fellow, Apollo hospital, Hyderabad, July 2014 to June 2017
• Senior Registrar, Medical Oncology, Fortis, Mumbai, December 2013 to June 2014
• DNB scholar, Internal Medicine, Breach Candy Hospital, Mumbai, February 2009 to February 2012
• Medical Officer, Hemato-Oncology, Lilavati Hospital, Mumbai, June 2008- January 2009

• Dr. Viraj won a scholarship award (UICC fellowship from City of Hope, Duarte USA, June 2016) for the project “HAI (Hepatic Arterial Infusion) chemotherapy for liver-limited metastatic colorectal cancer”.
• Published numerous research articles in leading journals such as the Journal of Surgical Oncology, Frontiers in Oncology, and JCO Global Oncology.Contributed editorials and review articles to prominent journals, including the Indian Journal of Cancer and theInternational Journal of Medical and Pediatric Oncology (IJMPO).
• Presented at national and international oncology conferences, sharing expertise in GI malignancies and innovative treatment strategies.
• Recognized for managing challenging cases like advanced biliary tract cancers, metastatic colorectal cancer, and unresectable hepatocellular carcinoma.

• American Society of Clinical Oncology (ASCO)
• European Society for Medical Oncology (ESMO)
• North American Neuroendocrine Tumor Society (NANETS)
• IHPBA
• ISMPO
• IJMPO – associate editor for GI cancers

• GI Oncology
• Colorectal Cancers
• Pancreaticobiliary Cancers

• Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) – Results from the Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP) Study – Journal of Gastrointestinal Oncology, June 2023 – doi: 10.1007/s12029-023-00936-1
• HER2 ‘neu’ promise for mCRC – Review article in International Journal of Molecular and Immuno Oncology, February 2023 – doi: 10.25259/IJMIO_30_2022
• Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2-overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study. SAGE Open Med Case Rep. 2022 Nov 27;10:2050313X221137447. doi: 10.1177/2050313X221137447
• Time for colorectal cancer screening in India! – Editorial in Indian Journal of Cancer, July 2021 – doi:10.4103/ijc.ijc_918_21
• Systemic Treatment for Metastatic Colorectal Cancer in the Era of Precision Medicine – Review article in Journal of Surgical Oncology, April 2019 – doi: 10.1002/jso.25421
• Impressive response to dual mutant intrahepatic cholangiocarcinoma – Journal of Gastrointestinal Oncology, December 2016 – doi: 10.21037/jgo.2016.09.13
• Pulmonary artery thrombosis mimicking disease progression in metastatic renal cell carcinoma while on sunitinib. Indian J Cancer 2016 – doi: 10.4103/0019-509X.180852
• PRES, the most uncommon side effect of one of the commonest chemotherapy regimen, FOLFOX. Apollo Medicine March 2015; doi: 10.1016/j.apme.2015.02.002